Abstract: There is a rapidly expanding growth of radiopharmaceuticals worldwide leading to exciting new opportunities in diagnosis and therapy with the potential to transform clinical care.  Ensuring effective translation of radiopharmaceuticals from preclinical pipelines to clinical implementation is important but complex.  In a landscape that has changed significantly for research in radiopharmaceuticals in the last decade, exploring current progress, challenges and opportunities will highlight how we may harness the potential of radiopharmaceuticals for the future.

Bio: Ros Francis is an academic Nuclear Medicine specialist who has established an innovative and highly collaborative research career focused on clinical trials, novel radiopharmaceuticals for imaging and therapy, and innovative approaches for quantitative imaging. Her expertise spans diverse fields including oncology, cardiology, neurology and inflammatory diseases, with a focus on research translation. Ros is passionate about nuclear medicine clinical trials and has been integral in the establishment of Australasian Radiopharmaceutical Trials Network (ARTnet), for which she has been Scientific Chair since 2014.

Ros relocated to Brisbane in 2024 from Western Australia and is enjoying new opportunities in Queensland’s vibrant and innovative biodiscovery ecosystem. As Director of Herston Imaging Research Facility and Senior Group Leader AIBN, Ros aims to lead translational research to improve outcomes for patients.